Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma

被引：43
作者：
Hegazy M.A.F. [1 ]
Hegazi R.A.F. [3 ,4 ,5 ]
Elshafei M.A. [1 ]
Setit A.E. [1 ]
Elshamy M.R. [2 ]
Eltatoongy M. [2 ]
Halim A.A.F. [1 ]
机构：
[1] Surgical Oncology Department, Mansoura University, Mansoura
[2] Obstetrics and Gynecology Department, Mansoura University, Mansoura
[3] Nuclear Medicine/Radiotherapy Department, Mansoura University, Mansoura
[4] Community Medicine Department, Mansoura University, Mansoura
[5] Faculty of Medicine, Mansoura University, Mansoura
来源：
World Journal of Surgical Oncology | / 3卷 / 1期
关键词：
Ovarian Carcinoma; Conventional Group; Advanced Ovarian Cancer; Epithelial Ovarian Carcinoma; Median Disease Free Survival;
D O I：
10.1186/1477-7819-3-57
中图分类号：
学科分类号：
摘要：
Background: Patients with advanced ovarian cancer should be treated by radical debulking surgery aiming at complete tumor resection. Unfortunately about 70% of the patients present with advanced disease, when optimal debulking can not be obtained, and therefore these patients gain little benefit from surgery. Neoadjuvant chemotherapy (NACT) has been proposed as a novel therapeutic approach in such cases. In this study, we report our results with primary surgery or neoadjuvant chemotherapy as treatment modalities in the specific indication of operable patients with advanced ovarian carcinoma (no medical contraindication to debulking surgery). Patients and methods: A total of 59 patients with stage III or IV epithelial ovarian carcinomas were evaluated between 1998 and 2003. All patients were submitted to surgical exploration aiming to evaluate tumor resectability. Neoadjuvant chemotherapy was given (in 27 patients) where optimal cytoreduction was not feasible. Conversely primary debulking surgery was performed when we considered that optimal cytoreduction could be achieved by the standard surgery (32 patients). Results: Optimal cytoreduction was higher in the NACT group (72.2%) than the conventional group (62.4%), though not statistically significant (P = 0.5). More important was the finding that parameters of surgical aggressiveness (blood loss rates, ICU stay and total hospital stay) were significantly lower in NACT group than the conventional group. The median overall survival time was 28 months in the conventional group and 25 months in NACT group with a P value of 0.5. The median disease free survival was 19 months in the conventional group and 21 months in NACT group (P = 0.4). In multivariate analysis, the pathologic type and degree of debulking were found to affect the disease free survival significantly. Overall survival was not affected by any of the study parameters. Conclusion: Primary chemotherapy followed by interval debulking surgery in select group of patients doesn't appear to worsen the prognosis, but it permits a less aggressive surgery to be performed. © 2005 Hegazy et al; licensee BioMed Central Ltd.
引用
收藏
页数：8
相关论文
共 29 条
  • [1] Randall T.C., Rubin S.C., Cytoreductive surgery for ovarian cancer, Surg. Clin. North Am., 81, pp. 871-876, (2001)
  • [2] Ovarian cancer screening, treatment and follow up, Jama, 273, pp. 491-497, (1995)
  • [3] Griffith C.T., Parker L.M., Lee S., Finkler N.J., The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: Long term results, Int. J. Gynacol. Cancer, 12, pp. 323-331, (2002)
  • [4] Eisenkop S.M., Spiretos N.M., Montag T.W., Nalick R.H., Wang H., The impact subspecialty training on the management of advanced ovarian cancer, Gynacol. Oncol., 46, pp. 203-209, (1992)
  • [5] Frei E., Clinical cancer research, an embattled species, Cancer, 50, pp. 1979-1992, (1982)
  • [6] Van der Woude H.J., Bloem J.L., Verstrate K.L., Osteosarcoma and Ewing sarcoma after neoadjuvant chemotherapy: Value of dynamic MR imaging in detecting viable tumor before surgery, Am. J. Roentgenol., 165, pp. 593-598, (1995)
  • [7] Bellaton E., Bertozzi A.I., Behar C., Chastagner P., Brisse H., Sainte-Rose C., Doz F., Desjardins L., Neoadjuvant chemotherapy for extensive Unilateral retinoblastoma, Br. J. Ophalmol., 87, pp. 327-329, (2003)
  • [8] Ansquer Y., Leblanc F., Clough K., Morice P., Dauplat J., Mathevet P., Lhomme C., Scherer C., Tigaud J.D., Benchaib M., Fourme E., Castaigne D., Querleu D., Dargent D., Neoadjuvant chemotherapy for unresectable ovarian carcinoma, Cancer, 91, pp. 2329-2334, (2001)
  • [9] Deraco M., Raspagliesi F., Kusamura S., Management of peritoneal surface component of ovarian cancer, Surg. Oncol. Clin. N. Am., 12, pp. 561-583, (2003)
  • [10] Gallo A., Frigerio L., Neoadjuvant chemotherapy and surgical considerations in ovarian cancer, Curr. Opin. Obstet. Gynacol., 1, pp. 25-31, (2003)
123